THANK YOU FOR SUBSCRIBING
A new cervical cancer treatment, a short course of chemotherapy before radiation, significantly boosts survival, eliminating death risk by 40 percent and reducing recurrence.
FREMONT, CA: A study published in The Lancet reveals that administering a short course of chemotherapy before radiation therapy significantly improves survival rates in patients with cervical cancer. This discovery marks a significant advancement in the fight against cervical cancer, utilizing readily available and cost-effective chemotherapy drugs.
The decade-long research, conducted across five countries, involved 500 cervical cancer patients. Participants were randomly assigned to receive either conventional treatment or a short course of chemotherapy followed by standard radiotherapy and chemotherapy. The results were striking: after five years, 80 percent of those in the chemotherapy group were still alive, compared to 72 percent in the conventional treatment group. Furthermore, the additional chemotherapy reduced the risk of disease recurrence by 35 percent and death by 40 percent.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Cervical cancer remains a global health concern, with over 660,000 new cases and 350,000 deaths worldwide in 2022. This new approach offers hope for improved outcomes, particularly for locally advanced cervical cancer, which has a high rate of recurrence and spread.
In the United States, where cervical cancer primarily affects women aged 35 to 44, this discovery holds immense promise. While HPV vaccination has led to a decline in cases among younger women, older, unvaccinated women remain at risk. This new treatment strategy, combined with ongoing efforts to expand HPV vaccine access and explore personalized therapies, offers a multi-pronged approach to combatting cervical cancer.
Experts highlight the trial's potential to address global health disparities. The chemotherapy drugs are widely accessible and affordable, making this strategy readily adoptable in low-resource settings. This breakthrough has the potential to redefine the standard of care in cervical cancer management worldwide, improving survival rates and reducing the burden of this disease.
More in News